Journal of VitreoRetinal Diseases最新文献_第3页

Pars Plana Vitrectomy Without Intravenous Anesthesia: Technique, Safety, and Outcomes. 无需静脉麻醉的玻璃体旁切除术：技术、安全性和结果。

IF 0.5

Journal of VitreoRetinal Diseases Pub Date : 2024-06-22 eCollection Date: 2024-09-01 DOI: 10.1177/24741264241260093

Karena X Tien, Erica Romo, Murtaza K Adam

{"title":"Pars Plana Vitrectomy Without Intravenous Anesthesia: Technique, Safety, and Outcomes.","authors":"Karena X Tien, Erica Romo, Murtaza K Adam","doi":"10.1177/24741264241260093","DOIUrl":"10.1177/24741264241260093","url":null,"abstract":"Introduction: To describe the technique, safety profile, and outcomes of performing pars plana vitrectomy (PPV) without intravenous (IV) anesthesia. Methods: This retrospective single-surgeon study comprised patients who had PPV without IV sedation between September 2018 and April 2022. Patients elected to undergo PPV without sedation or with oral sedation via sublingual triazolam administered 30 minutes preoperatively. Sub-Tenon bupivacaine and lidocaine were administered at the initiation of each case. A circulating nurse monitored patient vitals and electrocardiogram tracings without anesthesiologist support. Adverse events (AEs), visual acuity (VA), supplemental block administration, and reoperation rates were documented. Results: A total of 357 PPVs in 319 patients (mean age 68.75 ± 11.17 years [SD]; range, 36.82-98.57) were performed for surgical indications including vitreous floaters, intraocular lens or cataract surgery complications, retinal detachment, vitreous hemorrhage, and epiretinal membrane. Twenty-three cases were performed without sedation, and 334 were performed with oral sedation. For eyes with a follow-up longer than 1 month (n = 324), the preoperative VA of 0.68 ± 0.77 logMAR improved to 0.31 ± 0.46 logMAR postoperatively (P < .01). No intraoperative complications, systemic AEs, need to cease surgery prematurely, or conversion to IV sedation occurred. Five eyes (1.77%) required intraoperative supplemental sub-Tenon block administration, and 95% of patients who had a reoperation (n = 10) or fellow-eye surgery (n = 28) requested the same method of anesthesia without IV sedation. Conclusions: Vitreoretinal surgery with a sub-Tenon block and oral sedation can be safely performed without the support of an anesthesiologist. Additional trials are needed to further quantify patient comfort, surgeon experience, and complication rates.","PeriodicalId":17919,"journal":{"name":"Journal of VitreoRetinal Diseases","volume":null,"pages":null},"PeriodicalIF":0.5,"publicationDate":"2024-06-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11440523/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142361731","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Unexplained Acute Total Loss of Vision After Primary Scleral Buckle Surgery. 原发性巩膜扣带手术后不明原因的急性视力完全丧失。

IF 0.5

Journal of VitreoRetinal Diseases Pub Date : 2024-06-22 eCollection Date: 2024-09-01 DOI: 10.1177/24741264241260483

Greg Budoff, Alexander B Dillon, Adrian Au, Allan E Krieger, Steven D Schwartz

引用次数: 0

Multimodal Imaging of Unilateral Benign Yellow Dot Maculopathy. 单侧良性黄斑病变的多模态成像

IF 0.5

Journal of VitreoRetinal Diseases Pub Date : 2024-06-16 eCollection Date: 2024-09-01 DOI: 10.1177/24741264241260489

Michael Balas, Jovi Wong, Parnian Arjmand

引用次数: 0

Retrospective Large Database Study of Central Serous Chorioretinopathy Treatments and Visual Outcomes Analysis in the United States 美国中心性浆液性脉络膜视网膜病变治疗和视觉效果分析的大型回顾性数据库研究

IF 0.6

Journal of VitreoRetinal Diseases Pub Date : 2024-06-11 DOI: 10.1177/24741264241257021

Lauren A. Burgett, Nitika Aggarwal, John Latona, Matthew Driban, Jay K. Chhablani, Raj K. Maturi

{"title":"Retrospective Large Database Study of Central Serous Chorioretinopathy Treatments and Visual Outcomes Analysis in the United States","authors":"Lauren A. Burgett, Nitika Aggarwal, John Latona, Matthew Driban, Jay K. Chhablani, Raj K. Maturi","doi":"10.1177/24741264241257021","DOIUrl":"https://doi.org/10.1177/24741264241257021","url":null,"abstract":"Purpose: To evaluate a large database detailing the changes in visual acuity (VA) and central subfield thickness after various treatments for central serous chorioretinopathy (CSCR). Methods: A retrospective analysis was performed of patients with CSCR from January 2015 to September 2022 using the Vestrum Health Retina Database of aggregated de-identified electronic medical records from retina specialists in the United States. The cases of CSCR were categorized by age, sex, and treatment provided. Results: The annual incidence of CSCR was 1.72% (61 755 of 3 598 672 patient eyes), with a mean patient age of 53 years. Male eyes comprised 71.8% of the patient population. Eighty-five percent of patients received no treatment within 1 year of diagnosis. Of the patients needing treatment, 21% received thermal laser therapy, 23% photodynamic therapy, and 49% antivascular endothelial growth factor (anti-VEGF) intraocular injection. Patients not receiving treatment had the best baseline and 1-year VA. All treatment groups had an increased percentage of patients gaining letters compared with patients not receiving treatment. Conclusions: Although most patients did not require treatment, those who received treatment generally did well, with a large proportion having visual gain. Statistical analysis suggests treatment has a positive impact on VA outcomes. Patients receiving combination treatment were older and had the least visual gain of the treated cohorts. Younger patients with CSCR treated with anti-VEGF (and without a secondary diagnosis of macular degeneration) had the greatest increase in VA at 1 year.","PeriodicalId":17919,"journal":{"name":"Journal of VitreoRetinal Diseases","volume":null,"pages":null},"PeriodicalIF":0.6,"publicationDate":"2024-06-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141359957","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Central Retinal Artery Occlusion Leading to Diagnosis of Eosinophilic Granulomatous Polyangiitis After Adenovirus Vector COVID-19 Vaccination 接种腺病毒载体 COVID-19 疫苗后，视网膜中央动脉闭塞导致嗜酸性粒细胞性多血管炎确诊

IF 0.6

Journal of VitreoRetinal Diseases Pub Date : 2024-06-10 DOI: 10.1177/24741264241252588

Mary M. Moses, Nathan A. Fischer, Carly Elston, Bernard Dib

{"title":"Central Retinal Artery Occlusion Leading to Diagnosis of Eosinophilic Granulomatous Polyangiitis After Adenovirus Vector COVID-19 Vaccination","authors":"Mary M. Moses, Nathan A. Fischer, Carly Elston, Bernard Dib","doi":"10.1177/24741264241252588","DOIUrl":"https://doi.org/10.1177/24741264241252588","url":null,"abstract":"Purpose: To present a case of central retinal artery occlusion (CRAO) leading to the diagnosis of eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome) within 1 week of an adenovirus vector COVID-19 vaccination. Methods: A case was reviewed. Results: A 50-year-old man with atopic dermatitis and asthma presented with acute painless vision loss in 1 eye. An examination and imaging findings showed CRAO. Further evaluation found eosinophilia and elevated inflammatory markers. A workup for vasculitis showed elevated cytoplasmic-antineutrophil cytoplasmic antibody, perinuclear-antineutrophil cytoplasmic antibody, myeloperoxidase antibody, rheumatoid factor, and total immunoglobulin E. Skin biopsies were consistent with eosinophilic granulomatosis with polyangiitis. Steroids, cyclophosphamide, and mepolizumab were initiated. At 1 year, the patient’s systemic symptoms had improved but his vision had not. Conclusions: Few reports exist of CRAO associated with eosinophilic granulomatosis with polyangiitis, with no other instances related to an adenovirus vector COVID-19 vaccination. Treating a systemic vasculitis early can be vision saving in the fellow eye and prevent systemic life-threatening complications.","PeriodicalId":17919,"journal":{"name":"Journal of VitreoRetinal Diseases","volume":null,"pages":null},"PeriodicalIF":0.6,"publicationDate":"2024-06-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141361876","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Faricimab-Associated Retinal Vasculitis. 法尼单抗相关视网膜血管炎。

IF 0.5

Journal of VitreoRetinal Diseases Pub Date : 2024-05-29 eCollection Date: 2024-09-01 DOI: 10.1177/24741264241253899

Mohammad Z Siddiqui, Alia Durrani, Bradley T Smith

引用次数: 0

Intraoperative OCT-Guided Volumetric Measurements of Subretinal Therapy Delivery in Humans. 术中 OCT 引导下的人体视网膜下治疗容积测量。

IF 0.5

Journal of VitreoRetinal Diseases Pub Date : 2024-05-29 eCollection Date: 2024-09-01 DOI: 10.1177/24741264241253920

Nita G Valikodath, Jianwei D Li, William Raynor, Joseph A Izatt, Cynthia A Toth, Lejla Vajzovic

{"title":"Intraoperative OCT-Guided Volumetric Measurements of Subretinal Therapy Delivery in Humans.","authors":"Nita G Valikodath, Jianwei D Li, William Raynor, Joseph A Izatt, Cynthia A Toth, Lejla Vajzovic","doi":"10.1177/24741264241253920","DOIUrl":"https://doi.org/10.1177/24741264241253920","url":null,"abstract":"Purpose: To evaluate a recently developed technique using intraoperative optical coherence tomography (OCT) to measure subretinal tissue plasminogen activator (tPA) volumes in patients with submacular hemorrhage secondary to exudative age-related macular degeneration (AMD). Methods: Three patients (72 to 83 years old) had 25-gauge pars plana vitrectomy, subretinal tPA, and a partial gas fill. An investigational intraoperative OCT system with a modified widefield noncontact indirect viewing apparatus was used to image subretinal tPA blebs. Using the recently developed technique, the volume and surface area in the segmented region of interest were determined. Results: In each case, the delivered tPA volume measured from the syringe differed from the intraoperative OCT-measured subretinal tPA volume: Patient 1, 130 µL from syringe, 118 µL based on intraoperative OCT, 9% difference; Patient 2, 140 µL, 50 µL, 64%; Patient 3, 110 µL, 122 µL, 11%. The total bleb surface area was 129 mm2 in Patient 1, 55 mm2 in Patient 2, and 106 mm2 in Patient 3. Conclusions: This was the first human study to implement and evaluate intraoperative OCT image-based methods to obtain volumetric bleb measurements in patients receiving subretinal tPA for exudative AMD. This proof-of-concept study showed that intraoperative OCT-obtained bleb volume differed from intraoperative recordings, which could be explained by tPA delivery into the vitreous, efflux through the retinotomy, or human error. Intraoperative OCT can provide visualization and quantification of subretinal tPA bleb volume and surface area, which has implications for improved safety, efficacy, and analysis of the effects of subretinal drug delivery.","PeriodicalId":17919,"journal":{"name":"Journal of VitreoRetinal Diseases","volume":null,"pages":null},"PeriodicalIF":0.5,"publicationDate":"2024-05-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11418694/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142349355","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

From the Editor-in-Chief. 主编的话

IF 0.6

Journal of VitreoRetinal Diseases Pub Date : 2024-05-17 eCollection Date: 2024-05-01 DOI: 10.1177/24741264241245781

Timothy G Murray

引用次数: 0

Real-World Outcomes of the 0.19 mg Fluocinolone Acetonide Intravitreal Implant for Diabetic Macular Edema 0.19 毫克醋酸氟西诺龙玻璃体内植入剂治疗糖尿病黄斑水肿的实际效果

IF 0.6

Journal of VitreoRetinal Diseases Pub Date : 2024-05-16 DOI: 10.1177/24741264241247624

Christine Morozova, Lucas Humayun, Jonathan Kasper, Andy Morozov, Homayoun Tabandeh, David S. Boyer, P. Dayani, Firas M. Rahhal

{"title":"Real-World Outcomes of the 0.19 mg Fluocinolone Acetonide Intravitreal Implant for Diabetic Macular Edema","authors":"Christine Morozova, Lucas Humayun, Jonathan Kasper, Andy Morozov, Homayoun Tabandeh, David S. Boyer, P. Dayani, Firas M. Rahhal","doi":"10.1177/24741264241247624","DOIUrl":"https://doi.org/10.1177/24741264241247624","url":null,"abstract":"Purpose: To evaluate the real-world clinical and safety outcomes of a 0.19 mg fluocinolone acetonide intravitreal implant to treat diabetic macular edema (DME). Methods: This retrospective analysis comprised patients treated with a single fluocinolone acetonide intravitreal implant for the clinical indication of ME secondary to diabetic retinopathy. Primary outcomes included changes in best-corrected visual acuity (BCVA), central subfield thickness (CST), and frequency of DME-related treatments 12 months before and up to 36 months after fluocinolone acetonide administration. Safety outcomes were also assessed. Results: One hundred forty-eight eyes (115 patients) were followed for a mean (±SD) of 12.3 ± 4.2 months before and 29.4 ± 14.5 months after fluocinolone acetonide administration. A 0.8-letter decrease in the mean BCVA was observed at month 24. The BCVA was 70 letters (20/40 Snellen equivalent) or more (Early Treatment Diabetic Retinopathy Study) in 20.6% of eyes at baseline and 23.7% 24 months after implant administration. The mean CST was 379.9 μm and 323.7 μm, respectively. The CST was 300 μm or less in 58.7% of eyes at month 24 ( P < 0.001). The mean frequency of intravitreal antivascular endothelial growth factor injections or laser photocoagulation decreased from 4.9 to 1.5 per year after fluocinolone acetonide administration ( P < 0.001). Implant migration to the anterior chamber occurred in 3 eyes, 2 of which were vitrectomized and later required removal. Conclusions: The 0.19 mg fluocinolone acetonide intravitreal implant provided long-term stabilization of VA and macular anatomy in patients with DME, despite a significant reduction in treatment frequency.","PeriodicalId":17919,"journal":{"name":"Journal of VitreoRetinal Diseases","volume":null,"pages":null},"PeriodicalIF":0.6,"publicationDate":"2024-05-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140968400","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Heads-up 3-Dimensional Visualization to Enhance Video Endoscopy During Vitreoretinal Surgery 增强玻璃体视网膜手术视频内窥镜的平视三维可视化技术

IF 0.6

Journal of VitreoRetinal Diseases Pub Date : 2024-05-11 DOI: 10.1177/24741264241249527

Grace Baldwin, John B. Miller

引用次数: 0